Circle Cardiovascular Imaging

Deliberate B on the platform-not-algorithm principle, applied in its partial form. cvi42 is an established multi-vendor cardiovascular imaging reading platform spanning cardiac MRI and CT, and Plaque is an AI-enabled module added to it. The AI is real and separately cleared, quantifying total, calcified and non-calcified plaque, so this is not a C alongside ModMed or Indica Labs where the clearance belongs purely to the platform. But the company's franchise, install base and moat are the reading platform, not the plaque model. Same treatment as aetherAI, graded B as the partial case: a substantive algorithm inside a business whose centre of gravity is the platform.

Analysis tool under direct clinician control rather than an autonomous reporting system, and the on-premise design reinforces that: a Johns Hopkins user describes having immediate and interactive control over the coronary CCTA analysis, meaning the clinician drives the tool rather than receiving a finished report from a service. Graded B rather than A because no explicit statement of the human oversight model or the boundary of the tool's role was located, and the interactivity claim comes from a customer quotation rather than a stated design principle.

The weakest axis on this record. Located materials describe the AI as delivering fast, accurate and reproducible results for quantifying total, calcified and non-calcified plaque, but no accuracy figures, validation methodology, training data provenance or model description were retrieved. Against Elucid, which publishes its histology co-registration mechanism, and Artrya, which describes its Hounsfield Unit voxel approach and training data sources, this is materially less technical disclosure. Reproducibility in particular is asserted without a supporting figure, and reproducibility across readers and sites is precisely the open question the peer reviewed literature raises about this whole category.

No validation study specific to cvi42 Plaque was located. The company cites external context supporting the category rather than its own product, including expert recommendations that adding quantitative coronary plaque analysis may be useful for risk assessment and guiding preventive therapy in patients with visible plaque on coronary CTA. Category-level endorsement is not product-level evidence. Note the broader cvi42 platform has a long research presence in cardiac MRI, but that does not validate the plaque module cleared in October 2025. Contrast Heartflow with 600+ publications and Caristo with a Lancet cohort in the same lane.

The strongest position in the cardiovascular CT lane and the reason this record matters. On-premise deployment means patient imaging never leaves the institution for analysis, which the company states explicitly as evaluation without the need to send patient data to an external reading service. That is not a policy commitment about how data will be handled after transfer; it is an architecture in which the transfer does not occur. Every other indexed vendor in this lane, Heartflow, Elucid, Caristo and Artrya, moves imaging outside the enterprise. Compare Mendel, which earned similar credit for hosting inside the customer environment.

No published BAA terms located. Note that on-premise deployment materially reduces the surface a BAA would need to cover, since the vendor does not receive or process PHI in the analysis path, but the posture itself is undocumented.

No third party attestation such as SOC 2, ISO 27001 or ISO 13485 was retrieved at the time of review, which is a notable gap for a company whose central marketing claim is security and data control.

cvi42 Plaque received FDA 510(k) clearance announced October 2025 and is stated to be available for clinical use in the United States. Clean and clearly scoped to the specific module. Graded B rather than A because no 510(k) number was located, no other module clearances were enumerated in retrieved materials despite cvi42 spanning cardiac MRI and CT, and there is no equivalent of Heartflow's guideline recognition or Cognivue's documented De Novo. A straightforward clearance, well stated, without the depth that earns an A elsewhere in this lane.

No governance framework, subgroup analysis or bias evaluation was located at the time of review.

Genuine multi-vendor interoperability is the platform's heritage rather than a retrofit. cvi42 Plaque is stated to integrate into existing CT workflows and to be compatible with all major vendor systems, reflecting the platform's long standing as vendor-neutral cardiovascular reading software across MRI and CT. Being scanner-agnostic matters more here than in most categories, because the alternative in cardiovascular imaging is often an analysis package tied to one manufacturer's scanner, and the Nature Reviews Cardiology benchmarking of this field included exactly such manufacturer-bound options from Siemens and Canon. Same reasoning that earned Indica Labs an A for multi-vendor hardware support in pathology.

The defining strength of this vendor and the clearest data residency position in the lane. Fully on-premise: analysis runs inside the institution, so imaging data never crosses the boundary. This resolves residency, sovereignty and cross-border transfer questions structurally rather than contractually, and it removes the queue dependency inherent in send-out models, which the company frames as improved study processing times. For institutions in jurisdictions with data localisation requirements, or those unwilling to send imaging to a US or foreign cloud, this is effectively the only option among indexed cardiovascular CT vendors.

No licence price published, but the reimbursement position is described more precisely and more accurately than by most vendors in this lane, including the distinction others blur. The company states that Medicare covers AI-enabled coronary plaque analysis under Category III code 0625T with national payment set at $950, and separately that a permanent Category I code takes effect January 2026 replacing the previous Category III codes, noting this enables national pricing and physician reimbursement and signals that plaque quantification is now recognised as standard clinical care. It also notes higher base payments for the underlying CCTA exam. Getting the Category III to Category I transition right is exactly the distinction Caristo's split position makes consequential. Graded B rather than A because no vendor pricing basis is disclosed, unlike Artrya's published per-scan model.

Broader than the single-purpose plaque vendors because cvi42 is an established cardiovascular imaging platform spanning cardiac MRI and CT rather than a coronary-only product, serving cardiology departments and imaging centres, with reported use extending to specialised settings including adult congenital heart disease at Johns Hopkins. Graded B rather than A because coverage remains within cardiovascular imaging, and the specific breadth of cleared modules beyond Plaque was not enumerated in retrieved materials.